Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SOT102 |
Synonyms | |
Therapy Description |
SOT102 is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2)-targeted antibody linked to a derivative of the cytotoxic anthracycline PNU-159682, which potentially leads to impaired DNA replication and protein synthesis, resulting in killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SOT102 | SOT-102|SOT 102|SO N102|SO-N102|SON102 | CLDN18.2 Antibody 19 | SOT102 is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2)-targeted antibody linked to a derivative of the cytotoxic anthracycline PNU-159682, which potentially leads to impaired DNA replication and protein synthesis, resulting in killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05525286 | Phase Ib/II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 Gemcitabine + Nab-paclitaxel + SOT102 SOT102 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) | Recruiting | USA | FRA | ESP | CZE | BEL | 0 |